FDA Approves BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Alvogen Inc.
**LONDON --** AlvaPharma, a portfolio company of Aesica Pharmaceuticals, announced today the FDA approval of its buccal film formulation of buprenorphine and naloxone. This launch is set to provide an improved patient adherence profile and a distinct market position by addressing logistical barriers in opioid use disorder treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed